Scientech Research LLC Exelixis, Inc. Transaction History
Scientech Research LLC
- $353 Billion
- Q4 2024
A detailed history of Scientech Research LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Scientech Research LLC holds 24,022 shares of EXEL stock, worth $880,406. This represents 0.23% of its overall portfolio holdings.
Number of Shares
24,022
Previous 11,771
104.08%
Holding current value
$880,406
Previous $305 Million
161.88%
% of portfolio
0.23%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
566Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.08 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$859 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$561 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$418 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.8B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...